These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26909483)

  • 21. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vertebral fractures, osteoporosis and vitamin D levels in Chilean postmenopausal women].
    Rodríguez P JA; Valdivia C G; Trincado M P
    Rev Med Chil; 2007 Jan; 135(1):31-6. PubMed ID: 17369981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between back pain and future vertebral fracture in postmenopausal women.
    Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
    Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
    Delmas PD; Ensrud KE; Adachi JD; Harper KD; Sarkar S; Gennari C; Reginster JY; Pols HA; Recker RR; Harris ST; Wu W; Genant HK; Black DM; Eastell R;
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3609-17. PubMed ID: 12161484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fracture Prevention with Zoledronate in Older Women with Osteopenia.
    Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wong S; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
    N Engl J Med; 2018 Dec; 379(25):2407-2416. PubMed ID: 30575489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
    Siris ES; Simon JA; Barton IP; McClung MR; Grauer A
    Osteoporos Int; 2008 May; 19(5):681-6. PubMed ID: 17968610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
    Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
    J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpress® (OSTEOXPRESS Study).
    Arboleya L; Díaz-Curiel M; Del Río L; Blanch J; Díez-Pérez A; Guañabens N; Quesada JM; Sosa M; Gómez C; Muñoz-Torres M; Ramírez E; Combalia J;
    Aging Clin Exp Res; 2010; 22(5-6):419-26. PubMed ID: 20110769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mineral density at different sites and vertebral fractures in Serbian postmenopausal women.
    Ilic Stojanovic O; Vuceljic M; Lazovic M; Gajic M; Radosavljevic N; Nikolic D; Andjic M; Spiroski D; Vujovic S
    Climacteric; 2017 Feb; 20(1):37-43. PubMed ID: 27860483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of vertebral fractures and quality of life in a sample of postmenopausal Brazilian women with osteoporosis.
    de Oliveira Ferreira N; da Silva RB; Arthuso M; Pinto-Neto AM; Caserta N; Costa-Paiva L
    Arch Osteoporos; 2012; 7():101-6. PubMed ID: 23225287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poverty is a risk factor for osteoporotic fractures.
    Navarro MC; Sosa M; Saavedra P; Lainez P; Marrero M; Torres M; Medina CD
    Osteoporos Int; 2009 Mar; 20(3):393-8. PubMed ID: 18773136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
    Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
    JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk factors for osteoporotic vertebral fracture in low-income community-dwelling elderly: a population-based prospective cohort study in Brazil. The São Paulo Ageing & Health (SPAH) Study.
    Domiciano DS; Machado LG; Lopes JB; Figueiredo CP; Caparbo VF; Takayama L; Oliveira RM; Menezes PR; Pereira RM
    Osteoporos Int; 2014 Dec; 25(12):2805-15. PubMed ID: 25092058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.
    Ensrud KE; Stock JL; Barrett-Connor E; Grady D; Mosca L; Khaw KT; Zhao Q; Agnusdei D; Cauley JA
    J Bone Miner Res; 2008 Jan; 23(1):112-20. PubMed ID: 17892376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.